Welcome to our dedicated page for SHUTTLE PHARMACTCLS HLDGS news (Ticker: SHPH), a resource for investors and traders seeking the latest updates and insights on SHUTTLE PHARMACTCLS HLDGS stock.
Shuttle Pharmaceuticals Holdings, Inc. develops cancer-therapy programs and drug-development technologies, with a focus on radiotherapy-related treatments and the Molecule.ai platform for molecular discovery and early-stage drug development. Its updates commonly address pipeline and platform development, including Ropidoxuridine, HDAC inhibitors, PSMA-B, PC-Rad Test and AI models for evaluating biological targets and therapeutic candidates.
Company news also includes financing activity, securities offerings, material agreements, shareholder-voting matters, governance updates and operating or financial results. The completed acquisition of Molecule.ai added an artificial-intelligence software asset to Shuttle Pharma's drug-discovery and predictive-analytics capabilities.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.